EN
关于我们
ABOUT US
Position:
Homepage
/
About Vcare

Company Profile

ABOUT US

Jiangsu Vcare PharmaTechCo., Ltd. (“Jiangsu Vcare”) was co-founded in 2010 by professors from China Pharmaceutical University and outstanding overseas returnees. After 14 years of development, the company has grown into a high-tech pharmaceutical company as well as a group company with two core businesses: R&Ds of innovative drugs and full industry chain CRO & CDMO services. We have more than 900 employees, including 16 doctors and nearly 200 masters with technicians accounting for over 84% of the total workforce. Our headquarter, which features 21,000m2 high-end R&D center, is situated in Biomedical Valley of Jiangbei New Area, Nanjing.

The parent company, Jiangsu Vcare, focuses on the independent R&Dof innovativedrugs,and provides differentiated solutions to unmet clinical needs. Currently, our innovative pipeline, with "anti-thrombotic new drug - Vicagrel" at its core, includes five innovative drug programs in clinical stages. Vicagrel capsules, as a National Major Scientific and Technological Special Project during the Twelfth Five-year Plan and Thirteenth Five-Year Plan Period, is a innovative oral P2Y12 receptor antagonist that can effectively inhibit platelet activation and aggregation, preventing thrombosis and thus preventing and treating heart, brain, and other arterial circulation disorders caused by high platelet aggregation. The Vicagrel’s Phase III clinical study is ongoing in China and the NDA is ready to be filed to US FDA. VC004 capsules, a second-generation NTRK inhibitor with the potential to overcome drug resistance, are in a pivotal Phase II clinical trial and we are about to submit a pre-NDA application to the Chian’s regulatory agency. VC005 tablets, a second-generation highly selective JAK1 inhibitor, are in Phase III clinical trials, focusing on autoimmune diseases such as atopic dermatitis and ankylosing spondylitis. All products have demonstrated significant clinical efficacy, high safety, and possess a strong likelihood of successful market launch. In addition, there are more than ten preclinical drug candidates under development, covering indications in the fields of cardiovascular and cerebrovascular, oncology, inflammation, and autoimmune diseases, and targeting the global market.

NanjingVcare, as a wholly-owned subsidiaryof Jiangsu Vcare, specializes in providingfullindustry chain CRO/CDMO services for pharmaceuticals, the business was equipped with nine high-end R&D technology platforms and has been created as a one-stop CRO/CDMO service platform integrating "chemical + pharmaceutical + medical" services. It ensures cash flow security and R&D support for the parent company. The affiliated manufacturing site, Hubei Tianshu Pharmaceutical, which covers approximately 21.5 acres, fully ensures controllable costs and a stable supply chain during the R&D and production stages (Official uwebsite:www.njvcare.com ).

We has pioneeringly established a business model that "driving cash flow through services to fundthe R&Dof innovative drugs”, forming a dual-engine driven, synergistic, and self-reliant operating system. Since 2021, we has completed multiple rounds of financing, with a total amount exceeding 1 billion yuan, and the innovative pipeline has continuously received high attention from the capital market..In 2024, we was successfully certified as a national-level "Little Giant" enterprise, which is also a representive of specialized, high-end and innovation-driven Small and Medium-sized Enterprises(SMEs),Before then, we had successively established a Jiangsu provincial enterprise academician workstation, a Nanjing postdoctoral innovation practice base, and an enterprise graduate workstation in collaboration with China Pharmaceutical University. We was also selected as one of Nanjing's 'unicorn' enterprises and included in the Nanjing cultivation library of innovative leading enterprises.

In the future, We will adhere to its founding principle of "The better Care, The better Medicines," continuously incubating and developing multiple innovative drugs aimed at differentiated solutions to clinical needs.

威凯尔
  • 14 year

    Professional R&D

  • 80 +

    Invention patent applications at home and abroad

  • 800 +

    Existing employees

  • 21000

    Enterprise R&D and production area

Development History

2021.2

2021

In 2021 Round A financing of 200 million yuan was completed.
2020.12

2020

In December, phase I clinical trial of vc004 project was launched
2020.10

2020

In 2020 and October, the company relocated a new site.
2019.6

2019

In June 2019, the phase II clinical trial of Vecagrelor was completed.
2018.5

2018

In May 2018, a phase II clinical trial of Vecagrelor was initiated.
2017.8

2017

In August, the recruitment, shooting and hanging of land for R & D headquarters in Nanjing Hi-tech Industrial Development Zone was completed.
2017.5

2017

In May and May 2017, the merger and acquisition of Nantong API Factory was completed.
2017.1

2017

In January 2017, the phase I clinical trial of Viagra was completed
2015.6

2015

In June, the phase I clinical trial of Viagra was started
2015.3

2015

In March 2015, with a valuation of 250 million yuan and a financing of 150 million yuan, it became an enterprise under the top 500 Yatai Group in China. In June 2015, it initiated the phase I clinical trial of Vicagrelor. In January, the phase I clinical trial of Vicagrelor was completed.
2014.2

2014

In February 2014, Vicat gray submitted a clinical application
2011

2011

In 2011, the Class 1.1 new drug Vicagrelor project was launched.
2010.8

2010

In 2010, in August, the company was established and currently has a registered capital of 35.4452 million yuan.

Qualifications

Honor

2011

In 2011, the company was rated as a private science and technology enterprise in Jiangsu Province; it was funded by the Technology Innovation Fund for Small and Medium-sized Scientific and Technological Enterprises of the Ministry of Science and Technology

2013

He was awarded the title of high-tech enterprise and small and medium-sized scientific and technological enterprise in Jiangsu Province in 2013 

2016

Established Nanjing Engineering Research and Technology Center in 2016; received funding from Jiangsu Key R & D Program (Social Development) project 

2017

In 2017, he was selected as an enterprise under the "Lantern Program" in Jiangbei New Area and established a graduate workstation for provincial enterprises; he was funded by the National "Thirteenth Five-Year Plan" Major Project 

2018

He won the third prize of Jiangsu Provincial Science and Technology Award and established the Academician Workstation of Jiangsu Enterprise in 2018

2019

In 2019, Nanjing Postdoctoral Innovation Practice Base, Southern Jiangsu National Independent Innovation Demonstration Zone and Jiangsu Provincial R & D enterprises were established to obtain the special funds for the transformation of scientific and technological achievements in Jiangsu Province 

2020

In 2020, it was recognized as the first batch of municipal headquarters enterprises in Nanjing in 2020, Nanjing Stunning Enterprise, Nanjing Research Center for Pharmaceutical Chemical Engineering, selected as the cultivation bank of innovative leading enterprises in Nanjing, and won the Science and Technology Innovation Award of Jiangbei New Area in Nanjing 

这是描述信息

Contact Us

Add:No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China

这是描述信息

Scan to see

Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.

中兴能源